Depressive effectiveness of vigabatrin (γ-vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells
Te-Yu Hung1,
Huai-Ying Ingrid Huang2,
Sheng-Nan Wu3,4,5 &
Chin-Wei Huang ORCID: orcid.org/0000-0003-3335-21876
BMC Pharmacology and Toxicology volume 22, Article number: 6 (2021) Cite this article
Vigabatrin (VGB) is an approved non-traditional antiepileptic drug that has been revealed to have potential for treating brain tumors; however, its effect on ionic channels in glioma cells remains largely unclear.
With the aid of patch-clamp technology, we investigated the effects of VGB on various ionic currents in the glioblastoma multiforme cell line 13–06-MG.
In cell-attached configuration, VGB concentration-dependently reduced the activity of intermediate-conductance Ca2+-activated K+ (IKCa) channels, while DCEBIO (5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one) counteracted the VGB-induced inhibition of IKCa channels. However, the activity of neither large-conductance Ca2+-activated (BKCa) nor inwardly rectifying K+ (KIR) channels were affected by the presence of VGB in human 13–06-MG cells. However, in the continued presence of VGB, the addition of GAL-021 or BaCl2 effectively suppressed BKCa and KIR channels.
The inhibitory effect of VGB on IKCa channels demonstrated in the current study could be an important underlying mechanism of VGB-induced antineoplastic (e.g., anti-glioma) actions.
Vigabatrin (VGB; γ-vinyl-gamma-aminobutyric acid [γ-vinyl-GABA]) is an approved antiepileptic drug, which is tailored as an adjuvant therapy for adults with refractory partial epilepsy; it is also used for the treatment of infantile spasms [1,2,3]. VGB is a structural analog of GABA, which irreversibly inhibits GABA-transaminase [4] and thus consequently increases levels of the inhibitory neurotransmitter GABA [5] in the brain. It has been shown to attenuate astroglial TWIK-related acid-sensitive K+ channel-1 in the hippocampus of seizure-sensitive gerbils [6]. Although most of VGB's effects are thought to be largely attributed to its GABA-ergic actions, its perturbations on the amplitude or gating of ionic effects are not clear.
The degree of functional expression in the intermediate-conductance Ca2+-activated K+ (IKCa) channels identified in glioma cells has recently been disclosed to interfere with the progression of malignant tumors [7]. IKCa channels (also known as KCa3.1, SK4, IKCa1, or KCNN4) are encoded by the KCNN4 gene. These channels have been cloned from human, mouse, or rat tissues; and, their activities are viewed to be associated with various cellular functions, which include hormonal secretion, cell motility or proliferation, and the regulation of Ca2+ influx or K+ efflux. All of these underlying mechanisms have been extensively studied in different types of non-excitable or neoplastic cells [8,9,10]. Alternatively, these channels have single-channel conductance of 20–60 pS and their biophysical and pharmacological profiles are viewed to be distinguishable from those of large- or small-conductance Ca2+-activated K+ channels [11, 12]. Of importance, the modulators of IKCa channels represent a potential therapeutic approach for a variety of diseases, particularly at malignant gliomas [7, 13].
VGB has been reported to decrease oligodendrocyte precursor cell proliferation as well as to increase the number of mature oligodendrocytes [14]. Interestingly, it has been also disclosed to have promising therapeutic efficacy for treating brain metastases in vivo [15]. However, the ionic mechanism through which VGB exerts anti-neoplastic actions is not yet determined. In this study, we sought to investigate its ionic mechanism which could be linked to anti-neoplastic actions in the glioblastoma multiforme cell line (i.e., human 13–06-MG glioma cells).
Chemicals, drugs and solutions
VGB ((±)-γ-vinyl-GABA, C6H11NO2) was acquired from Sigma-Aldrich (Merck Ltd., Taipei, Taiwan), GAL-021 was from MedChemExpress (Everything Biotech Ltd., New Taipei City, Taiwan), while DCEBIO (5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one) and TRAM-34 (1-((2-chlorophenyl)-(diphenyl)methyl)-1H-pyrazole) were from Tocris (Union Biomed, Taipei, Taiwan). Unless stated otherwise, for cell preparations, all culture media, fetal bovine serum, L-glutamine, and trypsin/EDTA were acquired from HyClone™ (Thermo Fisher; Level Biotech, Tainan, Taiwan); and, all other chemicals or reagents were of analytical grade.
The composition of the bathing solution (i.e., HEPES-buffered normal Tyrode's solution) was 136.5 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.53 mM MgCl2, 5.5 mM glucose, and 5.5 mM HEPES adjusted with NaOH to pH 7.4. To measure K+ currents, we backfilled the patch pipettes with an internal solution consisting of 130 mM K-aspartate, 20 mM KCl, 1 mM KH2PO4, 1 mM MgCl2, 3 mM Na2ATP, 100 μM Na2GTP, 0.1 mM EGTA, and 5 mM HEPES adjusted with KOH to pH 7.2 [16, 17]. To avoid the contamination of whole-cell Cl− currents, we substituted Cl− ions inside the pipette solution for aspartate.
For recording large-conductance Ca2+-activated (BKCa) channels, we kept cells in a high K+-bathing solution, and its composition was 145 mM KCl, 0.53 mM MgCl2, and 5 mM HEPES adjusted with KOH to 7.2, and the pipette solution contained 145 mM KCl, 2 mM MgCl2, and 5 mM HEPES titrated with KOH to 7.2. In this study, we obtained the reagent water from a Milli-Q water purification system (Merck, Ltd., Taipei, Taiwan). The culture medium and pipette solution were filtered on the day of use with an Acrodisc® syringe filter with a Supor® membrane (Bio-Check; New Taipei City, Taiwan).
Cell preparations
The glioblastoma multiforme cell line (13–06-MG) used in this study was kindly provided by Professor Dr. Carol A. Kruse (Department of Neurosurgery, Ronald Reagan UCLA Medical Center, LA, U.S.A). The 13–06-MG cells were cultured at a density of 106/ml in high glucose (4 g/l) Dulbecco's modified Eagle media (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 10 μg/ml streptomycin. Cells were maintained at 37 °C in a 5% CO2 incubator as monolayer cultures and thereafter sub-cultured weekly. Fresh media was added every 2–3 days in order to ensure a healthy cell population. To verify the presence of glial cells, we identified them by displaying glial fibrillary acidic protein, which is a cytoskeletal protein.
To evaluate concentration-dependent inhibition of VGB on the probability of IKCa channels that would be open, we kept 13–06-MG cells to be bathed in normal Tyrode's solution containing 1.8 mM CaCl2, and each cell examined was voltage-clamped at − 80 mV relative to the bath. The probability of channel opening was measured in the control or during cell exposure to different concentrations (0.3–100 μM) of VGB; and, these values were then compared with those taken after the addition of TRAM-34 (3 μM). TRAM-34 is a known selective blocker of IKCa channels. The concentration required to suppress 50% of channel activity was determined by means of a Hill function:
$$ Percentageinhibition=\frac{E_{\mathrm{max}}\times {\left[C\right]}^{n_H}}{IC_{50}^{n_H}+{\left[C\right]}^{n_H}}, $$
where IC50 or nH is the concentration required for a 50% inhibition or the Hill coefficient, respectively; [C] the VGB concentration; and Emax the maximal reduction in channel opening probability (i.e., TRAM-34-sensitive channel activity) caused by VGB.
Linear or nonlinear curve-fitting (e.g., sigmoidal or exponential curve) to the data sets collected was performed by using either Microsoft Excel® (Redmond, WA) or OriginPro 2016 (Microcal). The experimental data are presented as the mean ± standard error of the mean (SEM) with sample sizes (n) indicating the number of 13–06-MG cells from which the results was acquired. The Student's t-test (paired or unpaired) or one-way analysis of variance (ANOVA) followed by a post-hoc Fisher's least-significant difference test, was performed to analyze multiple groups. The data were examined using a nonparametric Kruskal-Wallis test, subject to possible violation in the normality underlying ANOVA. Differences were considered statistically significant when the P-value was below 0.05.
VGB and the activity of IKCa channels in 13–06-MG cells
Experiments to evaluate the effect of VGB on IKCa channel activity were performed. In this set of experiments, 13–06-MG cells were bathed in normal Tyrode's solution containing 1.8 mM CaCl2 and single-channel current recordings were made. The probability of IKCa channel opening was measured at − 80 mV relative to the bath. In the presence of VGB, the IKCa channels were significantly less likely to be open, compared with the control (Fig. 1a). Similar effects were observed after TRAM-34 was added to the control group (Fig. 1b). IKCa channels that were closed in VGB-treated cells were reopened after the cells were treated with DCEBIO, an activator of IKCa channels. This data is summarized in Fig. 1c, which shows the effects of control, extracellular Ca2+ (0 mM), extracellular Ca2+ (3.6 mM), VGB, TRAM-34 (3 μM), and VGB (10 μM) plus DCEBIO (10 μM) on IKCa channel activity. Each bar indicates the mean ± SEM (n=9–11). As cells were exposed to Tyrode's solution containing 3.6 mM CaCl2, the presence of VGB (10 μM) effectively decreased IKCa channel activity, while it had minimal effect on it in cells bathed in Ca2+-free Tyrode solution. Therefore, the results enable us to indicate that the IKCa channels measured from these cells was sensitive either to the level of extracellular Ca2+ or to block by TRAM-34, and that VGG-mediated inhibition of IKCa channel was attenuated by further application of DCEBIO.
Effect of VGB on the activity of intermediate-conductance Ca2+-activated K+ (IKCa) channels expressed in human 13–06-MG glioma cells. In this set of experiments, 13–06-MG cells were bathed in normal Tyrode's solution containing 1.8 mM CaCl2 and single-channel current recordings were made. The probability of IKCa channels opening was measured at − 80 mV relative to the bath. a Original current traces for IKCa channels obtained in the absence (left) and presence (right) of VGB (10 μM). Note that channel opening gives a downward deflection in current. b Original IKCa channel traces taken in the absence (upper) and presence (lower) of TRAM-34 (3 μM). c Summary of the data showing the effects of control, extracellular Ca2+ (0 mM), extracellular Ca2+ (3.6 mM), VGB, TRAM-34 (3 μM), and VGB (10 μM) plus DCEBIO (10 μM) on IKCa channel activity. The probability of IKCa channel opening was measured at − 80 mV relative to the bath. Each bar indicates the mean ± SEM (n=9–11). *Significantly different from control (i.e., in the presence of 1.8 mM Ca2+, but VGB was not present) (P< 0.05) and **significantly different from the VGB alone group (P< 0.05)
VGB effect on single-channel conductance of IKCa channels
How VGB treatment affected IKCa channels at different membrane potentials was further evaluated. Plots of current amplitude as a function of holding potential were then constructed. Single-channel amplitudes at the potentials ranging between − 80 and + 20 mV were measured. Original current traces of single channel activities at the different levels of membrane potential relative to the bath obtained in the absence (left) and presence (right) of VGB (10 μM) were shown (Fig. 2a). The single-channel conductance of IKCa channels calculated from a linear I-V relationship in the control was further calculated to yield 32.4±4 pS (n=9) over the voltage ranging between − 80 and + 20 mV (Fig. 2b). Of notice, the conductance measured at negative potentials was greater than that at positive voltages. However, the single-channel slope conductance (32.1±4 pS; n=9, P> 0.05) of IKCa channels was not significantly changed after VGB (10 μM) treatment, despite the observed reduction in the probability of channel openings.
Original current traces of single channel activities and the association between single IKCa channel amplitude and membrane potential obtained in the absence (left) and presence of VGB (10 μM). a Original IKCa channel currents obtained with or without the addition of VGB (10 μM). The number shown at the left lower corner of each panel indicates the level of membrane potential relative to the bath. The downward deflection is the opening event of the channel. b The association between single IKCa channel amplitude and membrane potential (i.e., Δvoltage) in the absence (■) and presence (□) of 10 μM VGB (mean ± SEM; n=8–13 for each point). Note that the single-channel conductance of IKCa channels over the voltage range between − 80 and − 40 mV obtained in the absence (32.4 pS) and presence (32.1 pS) of VGB did not differ significantly in human 13–06-MG cells
Concentration-dependent inhibitory effect of VGB on the activity of IKCa channels
The relationship of the percentage suppression of IKCa channel activity versus VGB concentration was further analyzed. In this set of experiments, each cell was maintained at --80 mV relative to the bath, and the channel open-state probabilities in the absence and presence of different VGB concentrations were measured. As depicted in Fig. 3, the addition of VGB (0.3–100 μM) suppressed the activity of IKCa channels in a concentration-dependent manner. The IC50 value required for its inhibitory effect on channel activity in 13–06-MG cells was calculated to be 4.21 μM, and it at a concentration of 100 μM nearly abolished the probability of channel openings. Findings from these observations led us to indicate that VGB is able to exert a depressive action on the activity of IKCa channels expressed in 13–06-MG cells.
Concentration-response curve for VGB-induced suppression of IKCa channels recorded in human 13–06-MG cells (mean ± SEM; n=11–14 for each point). VGB was added at various concentrations (0.3–100 μM) to the bath, and the activity of IKCa channels was detected at − 80 mV relative to the bath. The smooth curve was well fitted with a least-squares procedure to a modified Hill function
Effect of VGB and VGB plus GAL-021 on the probability of BKCa channel opening
We further examined whether the presence of VGB could affect the activity of BKCa channels in 13–06-MG cells. In these experiments, cells were immersed in a high-K+ solution that contained 1.8 mM CaCl2, and the examined cells were held at + 80 mV. As the cells were exposed to 10 μM VGB, the probability of BKCa channels opening was not altered (Fig. 4). However, following the addition of GAL-021 (10 μM) channel activity was significantly decreased. GAL-021 has been previously reported to be a blocker of BKCa channels [18]. Unlike IKCa channels, which were suppressed by VGB, the BKCa channels were resistant to being blocked by this agent.
The inability of VGB to alter the activity of BKCa channels was recorded in human 13–06-MG cells. The experiments were conducted under cell-attached configuration. The cells were bathed in a high-K+ solution containing 1.8 mM CaCl2, and the examined cells were clamped at a level of + 80 mV. a Original trace of single BKCa channels obtained in the control (upper) and after the addition of 10 μM VGB (middle) or 10 μM VGB plus 10 μM GAL-021 (lower). The upward deflection indicates the opening event of the channel. b Summary bar graph of the effects of VGB or VGB plus GAL-021 on the probability of BKCa channel opening (mean ± SEM; n=7 for each bar). *Significantly different from the control or 10 μM VGB alone (P< 0.05)
Effect of VGB and VGB plus BaCl2 on KIR channel activity
In another set of single-channel current recordings, we tested whether other K+ channels (i.e., KIR channels) could be affected by the presence of VGB. Cells were bathed in Ca2+-free Tyrode's solution and the holding potential was set at − 80 mV relative to the bath. However, the presence of 10 μM VGB was unable to produce any modifications in KIR channel activity in these cells (Fig. 5). However, the subsequent addition of 1 mM BaCl2 in the continued presence of 10 μM VGB, effectively suppressed the probability of channel opening. BaCl2 is regarded as an inhibitor of KIR channels [19].
Failure of VGB to modify the activity of KIR channels in human 13–06-MG cells. In this set of experiments, we bathed cells in Ca2+-free Tyrode's solution and, during the recording, we backfilled the pipette by using K+-containing solution. The activity of KIR channels was detected at − 80 mV relative to the bath. a Single KIR channels obtained in the absence (upper) and presence (lower) of 10 μM VGB. The downward deflection denotes the channel opening event. b Summary bar graph depicting the effect of VGB and VGB plus BaCl2 on the activity of KIR channels in human 13–06-MG cells (mean ± SEM; n=7 for each bar). *Significantly different from the control or 10 μM VGB alone (P< 0.05). VGB: 10 μM VGB; BaCl2: 1 mM BaCl2
VGB is an anti-epileptic agent that is viewed to be an inhibitor of gamma-aminobutyric acid (GABA) breakdown. It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2, 3]. In the present study, we found that VGB dose-dependently lessened the probability of IKCa-channel openings, and that this reduction in channel activity is voltage-dependent and associated with a rise in mean closed time of the channel. The reduction in the channel open-state probability accounts primarily for its suppression in IKCa channel activity, owing to the inability to modify single-channel conductance of the channel. However, the activity of neither BKca nor KIR channels was conceivably perturbed by the presence of VGB. Therefore, in addition to its inhibition of GABA breakdown, this study revealed that VGB suppressed the activity of IKCa channels. This effect could be partly responsible for its suppression of neoplastic cells [20]. Therefore, awareness needs to be appropriately made when the effect of this compound is explained solely by its action on GABA-ergic dysregulation [14]. However, whether there is functional coupling between GABA-receptor(s) signaling and IKCa channel activity remains to be further studied.
The single-channel conductance of IKCa channels in human glioma cells (13–06-MG) was calculated to be 32 pS, a value similar to that of the prototypical IKCa channels present in other cell types [7, 13, 21], but less than that of BKCa channels [22, 23]. VGB-mediated inhibition of IKCa channel activity depends on membrane voltage and it is viewed to occur via a direct interaction with the KCa3.1 channel protein in glioma cells.
In this study, the IC50 value required for VGB-induced inhibition of IKCa channels was 4.21 μM. There is a wide range of serum/plasma concentrations (0.8–36 mg/L) associated with successful epilepsy treatment [24]. The concentration in cerebrospinal fluid was noted to be approximately 30–40% of plasma concentration, supporting that the IC50 value of VGB observed in this study could be of clinical or therapeutic relevance. Of note, the presence of VGB inhibits the activity of IKCa channels in humans at these relatively low concentrations, and in contrast to other compounds that disrupt the GABA neurotransmission, the VGB molecule is lipophilic and able to cross the blood-brain barrier [25]. Therefore, findings from the present observations could be important in determining VGB's in vivo anti-neoplastic mechanism.
Different types of kinetic behaviors perturbed by VGB might facilitate its inhibition of IKCa channel activity. VGB has no discernible effect on IKCa single-channel conductance; therefore, the VGB molecule unlikely acts within the channel's central pore. However, the mean closed time of the channel was lengthened in its presence. The activity of IKCa channels has been reported to regulate the proliferation of prostate cancer cells by controlling Ca2+ entry into these cells [8]. However, significant changes in neither BKCa nor KIR channel activity were observed in these cells. The effectiveness of VGB in inhibiting IKCa channels demonstrated presently in glioma cells does not result secondarily from the reduction of intracellular Ca2+ [26]. In this study, VGB inhibited IKCa channel activity within a few minutes in 13–06-MG cells. As the onset of inhibition was rapid, its action on channel activity was unlikely to ascribe from the binding to nuclear DNAs. The mechanism through which the VGB molecule interacts with IKCa channels tends to be direct and not genomic.
An earlier study in which immunolabelling of KCa3.1 channels was performed, disclosed that IKCa channels tended to be differentially expressed in excitatory and inhibitory neurons of the central nervous system [21]. Different isoforms of KCa3.1 might also be present in different tissues, including gliomas; however, whether VGB is capable of modifying different types of IKCa channels remains unknown. Further studies investigating the extent to which VGB-induced effects on glioma cells may be attributed to direct inhibitory perturbations on IKCa channels, are thus needed.
Of notice, the expression and function of glial Kir channels have been previously studied in retinal Müller glial cells, Schwann cells, astrocytes, and oligodendrocytes. Expression of Kir4.1 was identified in brain and retinal glial cells, while those of Kir2.1 and Kir2.3 were reported to be present in Schwann cells [27, 28]. Whether VGA can perturb the activity of different types of Kir channels in glial cells still remains to be further resolved.
Interestingly, one in vitro study suggested that VGB should not be used for prophylaxis or the short-term treatment of epilepsy in glioblastoma [20]. However, another report suggested that blocking GABA flux into the TCA cycle, either through genetic depletion of GAD1 or pharmacological treatment with VGB, suppressed aggressive metastatic outgrowth in the brain. Furthermore, it suggests that VGB might bring an additional benefit of stabilizing tumor-induced seizures [15].
Our previous study on temozolomide, which demonstrated its inhibitory effect on IKCa accompanied by membrane depolarization, could describe an important underlying mechanism of temozolomide-induced anti-neoplastic actions [29]. Supportively, it has been reported that ionizing radiation could stimulate BKCa channel activity, resulting in Ca2+/calmodulin-dependent kinaces II, leading to glioblastoma cell migration [30]. As KCa3.1 has been reported to confer radioresistance to breast cancer cells [31], strategies targeting KCa3.1 in anti-cancer treatment tend to be potential in modulating anti-neoplastic activity [32].
The inhibitory effect of VGB on IKCa channels demonstrated herein sheds light on and supports the potential of VGB on antineoplastic actions. The possible link between vigabatrin/IKCa channel activity and neoplastic cell behavior, including migration, spread, survival and proliferation is worth further investigation.
Our study demonstrated that the inhibitory effect of VGB on IKCa channels could be an important underlying mechanism of VGB-induced antineoplastic actions.
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
BKCa channel:
Large-conductance Ca2+-activated K+ channel
DCEBIO:
5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one
IC50 :
The concentration required for 50% inhibition
IKCa channel:
Intermediate-conductance Ca2+-activated K+ channel
KIR channel:
Inwardly rectifying K+ channel
SEM:
Standard error of mean
TRAM-34:
1-((2-chlorophenyl)-(diphenyl)methyl)-1H-pyrazole
Vigabatrin (γ-vinyl-GABA)
Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364:1773–8.
Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2008;4:CD001770.
Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2008;3:CD007302.
Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41:889–926.
Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27(Suppl 1):19–22.
Kim DS, Kim JE, Kwak SE, Choi HC, Song HK, Kimg YI, Choi SY, Kang TC. Up-regulated astroglial TWIK-related acid-sensitive K+ channel-1 (TASK-1) in the hippocampus of seizure-sensitive gerbils: a target of anti-epileptic drugs. Brain Res. 2007;1185:346–58.
Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14:1437–57.
Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, Urbain R, Gosset P, Delcourt P, Fleurisse L, Slomianny C, Dewailly E, Mauroy B, Bonnal JL, Skryma R, Prevarskaya N. Intermediate-conductance ca2+−activated k+ channels (ikca1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009;28:1792–806.
Liang Z, Chen L, McClafferty H, Lukowski R, MacGregor D, King JT, Rizzi S, Sausbier M, McCobb DP, Knaus HG, Ruth P, Shipston MJ. Control of hypothalamic-pituitary-adrenal stress axis activity by the intermediate conductance calcium-activated potassium channel, SK4. J Physiol. 2011;589:5965–86.
Ohya S, Niwa S, Kojima Y, Sasaki S, Sakuragi M, Kohri K, Imaizumi Y. Intermediate-conductance Ca2+- activated K+ channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia. J Pharmacol Exp Ther. 2011;338:528–36.
Schwab A, Fabian A, Hanley PJ, Stock C. Role of ion channels and transporters in cell migration. Physiol Rev. 2012;92:1865–913.
Leanza L, O'Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, Szabo I. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des. 2014;20:189–200.
Jensen BS, Strøbaek D, Olesen SP, Christophersen P. The Ca2+-activated K+ channel of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets. 2001;2:401–22.
Zonouzi M, Scafidi J, Li P, McEllin B, Edwards J, Dupree JL, Harvey L, Sun D, Hübner CA, Cull-Candy SG, Farrant M, Gallo V. GABAergic regulation of cerebellar NG2 cell development is altered in perinatal white matter injury. Nat Neurosci. 2015;18:674–82.
Schnepp PM, Lee DD, Guldner IH, O'Tighearnaigh TK, Howe EN, Palakurthi B, Eckert KE, Toni TA, Ashfeld BL, Zhang S. GAD1 upregulation programs aggressive features of cancer cell metabolism in the brain metastatic microenvironment. Cancer Res. 2017;77:2844–56.
Hung TY, Chu FL, Wu DC, Wu SN, Huang CW. The Protective Role of Peroxisome Proliferator-Activated Receptor-Gamma in Seizure and Neuronal Excitotoxicity. Mol Neurobiol. 2019;56:5497–506.
Lai MC, Tzeng RC, Huang CW, Wu SN. The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents. Biomolecules. 2019;9:E638.
Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology. 2014;121:459–68.
Wang CL, Tsai ML, Wu SN. Evidence for mitoxantrone-induced block of inwardly rectifying K+ channels expressed in the osteoclast precursor RAW 264.7 cells differentiated with lipopolysaccharide. Cell Physiol Biochem. 2013;30:687–701.
Lee CY, Lai HY, Chiu A, Chan SH, Hsiao LP, Lee ST. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016;127:445–53.
Turner RW, Kruskic M, Teves M, Scheidl-Yee T, Hameed S, Zamponi GW. Neuronal expression of the intermediate conductance calcium-activated potassium channel kca3.1 in the mammalian central nervous system. Pflugers Arch. 2015;467:311–28.
Hung TY, Huang CW, Wu SN. High ability of zileuton ((±)-1-(1-benzo [b]thien-2-ylethyl)-1-hydroxyurea) to stimulate I K(Ca) but suppress I K(DR) and I K(M) independently of 5-lipoxygenase inhibition. Eur J Pharmacol. 2020;887:173482.
Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ. Seizure reduction in a low-grade glioma: More than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry. 2015;86:366–73.
McMillin GA, Krasowski MD. Therapeutic Drug Monitoring of Newer Antiepileptic Drugs. In: Clinical Challenges in Therapeutic Drug Monitoring; 2016.
Silverman RB. The organic chemistry of drug design and drug action. In: Chapter 5. Enzyme inhibition and inactivation. 2nd ed. Burlington: Elsevier; 2004. p. 290.
McFerrin MB, Turner KL, Cuddapah VA, Sontheimer H. Differential role of IK and BK potassium channels as mediators of intrinsic and extrinsic apoptotic cell death. Am J Physiol Cell Physiol. 2012;303:C1070–8.
Horie Y, Kurachi Y. Glial inwardly rectifying potassium channels. In: Kurachi Y, Jan LY, Lazdunski M, editors. Potassium ion channels: molecular structure, function, and diseases. Current Topics in Membranes, vol. 46. San Diego: Academic; 1999. p. 471–82.
Chapter Google Scholar
Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010;90:291–366.
Yeh PS, Wu SJ, Hung TY, Huang YM, Hsu CW, Sze CI, Hsieh YJ, Huang CW, Wu SN. Evidence for the Inhibition by temozolomide, an imidazotetrazine family alkylator, of intermediate-conductance Ca2+-activated K+ channels in glioma cells. Cell Physiol Biochem. 2016;38:1727–42.
Steinle M, Palme D, Misovic M, Rudner J, Dittmann K, Lukowski R, Ruth P, Huber SM. Ionizing radiation induces migration of glioblastoma cells by activating BK K(+) channels. Radiother Oncol. 2011;101:122–6.
Mohr CJ, Gross D, Sezgin EC, Steudel FA, Huber RO, SM LR. KCa 3.1 channels confer radioresistance to breast cancer cells. Cancers (Basel). 2019;11:1285.
Mohr CJ, Steudel FA, Gross D, Ruth P, Lo WY, Hoppe R, Schroth W, Brauch H, Huber SM, Lukowski R. Cancer-associated intermediate conductance ca (2+)-activated k+ channel k (ca)3.1. Cancers (Basel). 2019;11:109.
We thank Ms. Jen-Nan Wu for her assistance on cell culture.
This study was supported in part by the National Cheng Kung University (D106-35A13, D107-F2519 and NCKUH-10709001 to SNW), Tainan City, Taiwan. SNW received a Talent Award for Outstanding Researchers from the Ministry of Education, Taiwan. This work was also supported in part by grants from the Ministry of Science and Technology, Taiwan (107–2314-B-006-018-, 107–2320-B-006-019-, 108–2320-B-006-023-, 109–2314-B-006 -034 -MY3 to CWH), and the National Cheng Kung University Hospital (20180254, 20190160 to CWH). The funding bodies did not play any roles in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Department of Pediatrics, Chi-Mei Medical Center, Tainan, Taiwan
Te-Yu Hung
Neuroscience Program, McGill University, Montréal, Quebec, Canada
Huai-Ying Ingrid Huang
Department of Physiology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City, 70101, Taiwan
Sheng-Nan Wu
Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan City, Taiwan
Department of Medical Research, China Medical University Hospital, China Medical University, Taichung City, Taiwan
Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City, 70101, Taiwan
Chin-Wei Huang
TYH, SNW, and CWH conceived the study. TYH, HYIH, SNW, and CWH performed the experiments. SNW and CWH participated in the statistical analysis. All authors approved the final manuscript. Each author contributed substantially during manuscript drafting or revision.
Correspondence to Sheng-Nan Wu or Chin-Wei Huang.
Not applicable. This study did not involve human participants and animals.
Hung, TY., Huang, HY.I., Wu, SN. et al. Depressive effectiveness of vigabatrin (γ-vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells. BMC Pharmacol Toxicol 22, 6 (2021). https://doi.org/10.1186/s40360-021-00472-3
Received: 23 April 2020
Vigabatrin
Glioma cell